Search results
Here's Why You May Invest in Theravance (TBPH) Stock Now
Zacks via Yahoo News· 1 week agoTheravance Biopharma’s TBPH lead pipeline candidate is ampreloxetine, which is being developed for...
Viatris (VTRS) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates
Zacks via Yahoo News· 2 months agoEvaluate the expected performance of Viatris (VTRS) for the quarter ended March 2024, looking beyond...
Viatris (VTRS) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
Zacks via Yahoo News· 2 months agoWhile the top- and bottom-line numbers for Viatris (VTRS) give a sense of how the business performed...
Viatris (VTRS) Q1 Earnings and Revenues Miss Estimates
Zacks via Yahoo News· 2 months agoViatris (VTRS) delivered earnings and revenue surprises of -1.47% and 2.12%, respectively, for the...
Theravance (TBPH) Q1 Earnings Top, Revenues Match Estimates
Zacks via Yahoo News· 2 months agoTheravance Biopharma, Inc. TBPH reported first-quarter 2024 adjusted net loss of 9 cents per share,...
Watch These 5 Drug Stocks for Q1 Earnings: Beat or Miss?
Zacks via Yahoo News· 2 months agoThe earnings season for the drug/biotech sector is now in its final lap, with two S&P 500 companies,...
Viatris (VTRS) Expected to Beat Earnings Estimates: Should You Buy?
Zacks via Yahoo News· 2 months agoViatris (VTRS) possesses the right combination of the two key ingredients for a likely earnings beat...
Viatris (VTRS) to Report Q1 Earnings: Is a Beat in Store?
Zacks via Yahoo News· 2 months agoViatris VTRS, a global healthcare company, is scheduled to report first-quarter results on May 9,...
Viatris' (VTRS) Q1 Earnings & Sales Lag Estimates, Stock Down
Zacks via Yahoo News· 2 months agoViatris Inc. VTRS delivered adjusted earnings of 67 cents per share in the first quarter of 2024,...
Viatris (VTRS)'s Technical Outlook is Bright After Key Golden Cross
Zacks via Yahoo News· 10 months agoFrom a technical perspective, Viatris Inc. (VTRS) is looking like an interesting pick, as it just...